Pfizer (NYSE: PFE )
could use another blockbuster right now, and data presented from the
phase 2 PALOMA-1 study for its CDK 4/6 inhibitor palbociclib over the
weekend suggests it likely has one. The only major issue now could be
the Street's already aggressive expectations, particularly as they
pertain to Pfizer filing for approval on the basis of phase 2 data and
getting to the market ahead of Lilly (NYSE: LLY ) and Novartis (NYSE: NVS ) .
Please continue here:
Pfizer Inc's Palbociclib Delivers the Goods
No comments:
Post a Comment